{"protocolSection": {"identificationModule": {"nctId": "NCT00643578", "orgStudyIdInfo": {"id": "Ivax-65307"}, "organization": {"fullName": "University of Florida", "class": "OTHER"}, "briefTitle": "Dose-response of Inhaled Formoterol Using Methacholine Challenge as a Bioassay", "officialTitle": "A Pilot Study to Evaluate the Dose-response of Inhaled Formoterol to Inhibit Airway Responsiveness to Methacholine in Patients With Mild Asthma"}, "statusModule": {"statusVerifiedDate": "2011-11", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2008-03"}, "primaryCompletionDateStruct": {"date": "2009-01", "type": "ACTUAL"}, "completionDateStruct": {"date": "2009-01", "type": "ACTUAL"}, "studyFirstSubmitDate": "2008-03-20", "studyFirstSubmitQcDate": "2008-03-20", "studyFirstPostDateStruct": {"date": "2008-03-26", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2011-08-05", "resultsFirstSubmitQcDate": "2011-11-08", "resultsFirstPostDateStruct": {"date": "2011-11-18", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2011-11-29", "lastUpdatePostDateStruct": {"date": "2011-12-05", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "University of Florida", "class": "OTHER"}, "collaborators": [{"name": "Teva Branded Pharmaceutical Products R&D, Inc.", "class": "INDUSTRY"}]}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "The purpose of this study is to find out whether a difference between two doses of formoterol can be detected by methacholine challenge.", "detailedDescription": "During the screening visit, subjects'vital signs (heart rate, blood pressure and temperature) will be measured and they will perform standard spirometry. If the results of this test are 70% of normal or greater, they will be examined by a physician, and blood (1 teaspoonful) and urine will be collected for routine laboratory tests (CBC and routine urinalysis). If they are a female, a pregnancy test will be performed.\n\nDuring the second visit, subjects will inhale 1 or 2 doses of formoterol, (Foradil Aerolizer 12 mcg/capsule) a long-acting bronchodilator and 1 hour later, perform a methacholine test.\n\nAt the end of the methacholine test, they will be given albuterol to reverse the effects of methacholine. On the third study day, they will repeat the second visit but with the opposite dose of Foradil."}, "conditionsModule": {"conditions": ["Asthma"], "keywords": ["formoterol", "methacholine challenge"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["NA"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "CROSSOVER", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 37, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "2", "type": "ACTIVE_COMPARATOR", "description": "a single dose of 24 mcg of formoterol", "interventionNames": ["Drug: formoterol", "Device: Dry Powder Inhaler (Twisthaler)"]}, {"label": "1", "type": "ACTIVE_COMPARATOR", "description": "a single dose of 12 mcg of formoterol", "interventionNames": ["Drug: formoterol", "Device: Dry Powder Inhaler (Twisthaler)"]}], "interventions": [{"type": "DRUG", "name": "formoterol", "description": "a single dose of 24 mcg of formoterol delivered by dry powder inhaler (Twisthaler)", "armGroupLabels": ["2"]}, {"type": "DRUG", "name": "formoterol", "description": "a single dose of 12 mcg of formoterol delivered by dry powder inhaler (Twisthaler)", "armGroupLabels": ["1"]}, {"type": "DEVICE", "name": "Dry Powder Inhaler (Twisthaler)", "description": "subjects inhaled deeply and forcefully and held their breath for 10 seconds for each dose", "armGroupLabels": ["1", "2"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Post-dose PC20", "description": "The PC20 is the provocational dose of methacholine causing a 20% drop in forced expiratory volume in the first second.", "timeFrame": "3-7 days after visits 1 and 2"}], "secondaryOutcomes": [{"measure": "FEV1", "description": "The forced expiratory volume in the first second, expressed as a percent predicted.", "timeFrame": "1 hour after dose"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Non-smoking male or female 18 60 years of age, with a previous diagnosis of asthma that has been stable for at least 4 weeks and which is unlikely to exacerbate during the study because of, for example, seasonal allergen exposure. Women of childbearing age must not be pregnant or nursing, and must be using an acceptable method of contraception.\n* Ability to perform ATS/ERS-acceptable and reproducible spirometry7\n* Screening FEV1 \u226570% of predicted for height, age, sex, and race when short-acting inhaled bronchodilators are withheld for at least 6 hours\n* At least a 20% decrease in FEV1 after inhaling \u22644 mg/mL of methacholine (i.e., a PC20 FEV1 \u22644 mg/mL)\n* Can be taught to use the dry powder device in accordance with the product's medication guide.\n* If using an oral inhaled or intranasal corticosteroid, dosage must be stable for at least 4 weeks.\n\nExclusion Criteria:\n\n* Allergy or sensitivity to inhaled methacholine, formoterol or to other \u03b22 agonists\n* Intolerance to other components of the inhaler or sensitivity to milk proteins\n* Cigarette smoking in past year or \\>10 pack-year smoking history\n* Respiratory tract infection within the last four weeks\n* History of severe asthma attack requiring hospitalization in the previous 12 months\n* Short course of oral and/or systemic corticosteroids in the past 4 weeks\n* Inability to withhold caffeinated beverages for 12 hours or medications for appropriate intervals prior to each methacholine challenge\n* Require treatment with beta-blockers (administered by any route), MAO inhibitors, tricyclic antidepressants, and/or maintenance therapy with systemic corticosteroids\n* History and/or presence of pulmonary conditions (including but not limited to cystic fibrosis and bronchiectasis) other than asthma\n* History of clinically-significant cardiovascular, renal, neurologic, liver or endocrine dysfunction. Patients with well-controlled hypertension, hypercholesterolemia or diabetes will not be excluded.\n* If female, a positive urine \u03b2-HCG test\n* Known or suspected substance abuse (e.g., alcohol, marijuana, etc.) and/or any other medical or psychological conditions that in the investigator's opinion should preclude study enrollment.", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "60 Years", "stdAges": ["ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Leslie Hendeles, PharmD", "affiliation": "University of Florida", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "University of Florida Asthma Research Lab", "city": "Gainesville", "state": "Florida", "zip": "32610-0486", "country": "United States", "geoPoint": {"lat": 29.65163, "lon": -82.32483}}]}, "referencesModule": {"references": [{"pmid": "3294976", "type": "BACKGROUND", "citation": "Ahrens RC, Harris JB, Milavetz G, Annis L, Ries R. Use of bronchial provocation with histamine to compare the pharmacodynamics of inhaled albuterol and metaproterenol in patients with asthma. J Allergy Clin Immunol. 1987 Jun;79(6):876-82. doi: 10.1016/0091-6749(87)90235-1."}, {"pmid": "1310456", "type": "BACKGROUND", "citation": "Blake KV, Hoppe M, Harman E, Hendeles L. Relative amount of albuterol delivered to lung receptors from a metered-dose inhaler and nebulizer solution. Bioassay by histamine bronchoprovocation. Chest. 1992 Feb;101(2):309-15. doi: 10.1378/chest.101.2.309."}, {"pmid": "15208585", "type": "BACKGROUND", "citation": "Hendeles L, Beaty R, Ahrens R, Stevens G, Harman EM. Response to inhaled albuterol during nocturnal asthma. J Allergy Clin Immunol. 2004 Jun;113(6):1058-62. doi: 10.1016/j.jaci.2004.03.046. Erratum In: J Allergy Clin Immunol. 2006 Apr;117(4):773."}, {"pmid": "10390425", "type": "BACKGROUND", "citation": "Parameswaran KN, Inman MD, Ekholm BP, Morris MM, Summers E, O'Byrne PM, Hargreave FE. Protection against methacholine bronchoconstriction to assess relative potency of inhaled beta2-agonist. Am J Respir Crit Care Med. 1999 Jul;160(1):354-7. doi: 10.1164/ajrccm.160.1.9812035."}, {"pmid": "10508813", "type": "BACKGROUND", "citation": "Ahrens RC, Hendeles L, Clarke WR, Dockhorn RJ, Hill MR, Vaughan LM, Lux C, Han SH. Therapeutic equivalence of Spiros dry powder inhaler and Ventolin metered dose inhaler. A bioassay using methacholine. Am J Respir Crit Care Med. 1999 Oct;160(4):1238-43. doi: 10.1164/ajrccm.160.4.9806101."}, {"pmid": "12417879", "type": "BACKGROUND", "citation": "Creticos PS, Adams WP, Petty BG, Lewis LD, Singh GJ, Khattignavong AP, Molzon JA, Martinez MN, Lietman PS, Williams RL. A methacholine challenge dose-response study for development of a pharmacodynamic bioequivalence methodology for albuterol metered- dose inhalers. J Allergy Clin Immunol. 2002 Nov;110(5):713-20. doi: 10.1067/mai.2002.129036."}, {"pmid": "16055882", "type": "BACKGROUND", "citation": "Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, Crapo R, Enright P, van der Grinten CP, Gustafsson P, Jensen R, Johnson DC, MacIntyre N, McKay R, Navajas D, Pedersen OF, Pellegrino R, Viegi G, Wanger J; ATS/ERS Task Force. Standardisation of spirometry. Eur Respir J. 2005 Aug;26(2):319-38. doi: 10.1183/09031936.05.00034805. No abstract available."}, {"pmid": "9872837", "type": "BACKGROUND", "citation": "Hankinson JL, Odencrantz JR, Fedan KB. Spirometric reference values from a sample of the general U.S. population. Am J Respir Crit Care Med. 1999 Jan;159(1):179-87. doi: 10.1164/ajrccm.159.1.9712108."}, {"pmid": "12006455", "type": "BACKGROUND", "citation": "Asmus MJ, Vaughan LM, Hill MR, Chesrown SE, Hendeles L. Stability of frozen methacholine solutions in unit-dose syringes for bronchoprovocation. Chest. 2002 May;121(5):1634-7. doi: 10.1378/chest.121.5.1634."}]}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "Of the 37 subjects who signed informed consent, 25 did not meet inclusion/exclusion criteria. The provocational dose of methacholine causing a 20% drop in forced expiratory volume in the first second (PC20FEV1) was not less than or equal to 4 mg/mL.", "recruitmentDetails": "Between April and November, 2008, the UF Asthma Research Lab recruited 37 patients for study.", "groups": [{"id": "FG000", "title": "Formoterol 12 First", "description": "a single dose of 12 mcg of formoterol was given first, then 24 mcg of formoterol"}, {"id": "FG001", "title": "Formoterol 24 First", "description": "a single dose of 24 mcg of formoterol was given first, then 12 mcg of formoterol"}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "6"}, {"groupId": "FG001", "numSubjects": "6"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "4"}, {"groupId": "FG001", "numSubjects": "6"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "0"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "All Participants", "description": "A single dose of 12 mcg and 24 mcg, on separate days, of formoterol were given."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "12"}]}], "measures": [{"title": "Age, Categorical", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "<=18 years", "measurements": [{"groupId": "BG000", "value": "0"}]}, {"title": "Between 18 and 65 years", "measurements": [{"groupId": "BG000", "value": "12"}]}, {"title": ">=65 years", "measurements": [{"groupId": "BG000", "value": "0"}]}]}]}, {"title": "Age Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "36.8", "spread": "14.5"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "7"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "5"}]}]}]}, {"title": "Region of Enrollment", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "United States", "categories": [{"measurements": [{"groupId": "BG000", "value": "12"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Post-dose PC20", "description": "The PC20 is the provocational dose of methacholine causing a 20% drop in forced expiratory volume in the first second.", "populationDescription": "Of the 12 subjects who qualified for randomization, 2 had a PC20 greater than 128 mg/mL (the maximum concentration of methacholine administered), after receiving 12 mcg of formoterol. Therefore, they were discontinued from the study since their PC20 would not be measurable with a higher dose of formoterol.", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "mg/mL", "timeFrame": "3-7 days after visits 1 and 2", "groups": [{"id": "OG000", "title": "12 Mcg Formoterol", "description": "low dose"}, {"id": "OG001", "title": "24 Mcg Formoterol", "description": "high dose"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "10"}, {"groupId": "OG001", "value": "10"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "7", "lowerLimit": "2", "upperLimit": "22"}, {"groupId": "OG001", "value": "16", "lowerLimit": "5", "upperLimit": "45"}]}]}]}, {"type": "SECONDARY", "title": "FEV1", "description": "The forced expiratory volume in the first second, expressed as a percent predicted.", "populationDescription": "Of the 12 subjects who qualified for randomization, 2 had a PC20 greater than 128 mg/mL (the maximum concentration of methacholine administered), after receiving 12 mcg of formoterol. Therefore, they were discontinued from the study since their PC20 would not be measurable with a higher dose of formoterol.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "percent predicted", "timeFrame": "1 hour after dose", "groups": [{"id": "OG000", "title": "12 Mcg of Formoterol", "description": "low dose"}, {"id": "OG001", "title": "24 Mcg of Formoterol", "description": "high dose"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "10"}, {"groupId": "OG001", "value": "10"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "88", "spread": "12"}, {"groupId": "OG001", "value": "91", "spread": "10"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "0", "eventGroups": [{"id": "EG000", "title": "Formoterol 12", "description": "A single dose of 12 mcg of formoterol was administered.", "seriousNumAffected": 0, "seriousNumAtRisk": 10, "otherNumAffected": 0, "otherNumAtRisk": 10}, {"id": "EG001", "title": "Formoterol 24", "description": "A single dose of 24 mcg of formoterol was administered.", "seriousNumAffected": 0, "seriousNumAtRisk": 10, "otherNumAffected": 0, "otherNumAtRisk": 10}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictiveAgreement": false}, "pointOfContact": {"title": "Dr. Leslie Hendeles", "organization": "University of Florida Asthma Research Lab", "email": "hendeles@cop.ufl.edu", "phone": "352-273-6027"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000001249", "term": "Asthma"}], "ancestors": [{"id": "D000001982", "term": "Bronchial Diseases"}, {"id": "D000012140", "term": "Respiratory Tract Diseases"}, {"id": "D000008173", "term": "Lung Diseases, Obstructive"}, {"id": "D000008171", "term": "Lung Diseases"}, {"id": "D000012130", "term": "Respiratory Hypersensitivity"}, {"id": "D000006969", "term": "Hypersensitivity, Immediate"}, {"id": "D000006967", "term": "Hypersensitivity"}, {"id": "D000007154", "term": "Immune System Diseases"}], "browseLeaves": [{"id": "M27137", "name": "Respiratory Aspiration", "relevance": "LOW"}, {"id": "M4556", "name": "Asthma", "asFound": "Asthma", "relevance": "HIGH"}, {"id": "M5258", "name": "Bronchial Diseases", "relevance": "LOW"}, {"id": "M14977", "name": "Respiratory Tract Diseases", "relevance": "LOW"}, {"id": "M11168", "name": "Lung Diseases", "relevance": "LOW"}, {"id": "M11170", "name": "Lung Diseases, Obstructive", "relevance": "LOW"}, {"id": "M10018", "name": "Hypersensitivity", "relevance": "LOW"}, {"id": "M14967", "name": "Respiratory Hypersensitivity", "relevance": "LOW"}, {"id": "M10020", "name": "Hypersensitivity, Immediate", "relevance": "LOW"}, {"id": "M10200", "name": "Immune System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC08", "name": "Respiratory Tract (Lung and Bronchial) Diseases"}, {"abbrev": "BC23", "name": "Symptoms and General Pathology"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC20", "name": "Immune System Diseases"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000068759", "term": "Formoterol Fumarate"}], "ancestors": [{"id": "D000001993", "term": "Bronchodilator Agents"}, {"id": "D000001337", "term": "Autonomic Agents"}, {"id": "D000018373", "term": "Peripheral Nervous System Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000018927", "term": "Anti-Asthmatic Agents"}, {"id": "D000019141", "term": "Respiratory System Agents"}, {"id": "D000058666", "term": "Adrenergic beta-2 Receptor Agonists"}, {"id": "D000000318", "term": "Adrenergic beta-Agonists"}, {"id": "D000000322", "term": "Adrenergic Agonists"}, {"id": "D000018663", "term": "Adrenergic Agents"}, {"id": "D000018377", "term": "Neurotransmitter Agents"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}], "browseLeaves": [{"id": "M304", "name": "Formoterol Fumarate", "asFound": "Nicotine", "relevance": "HIGH"}, {"id": "M18666", "name": "Methacholine Chloride", "relevance": "LOW"}, {"id": "M5269", "name": "Bronchodilator Agents", "relevance": "LOW"}, {"id": "M20963", "name": "Anti-Asthmatic Agents", "relevance": "LOW"}, {"id": "M21137", "name": "Respiratory System Agents", "relevance": "LOW"}, {"id": "M20746", "name": "Adrenergic Agents", "relevance": "LOW"}, {"id": "M3670", "name": "Adrenergic beta-Agonists", "relevance": "LOW"}, {"id": "M3673", "name": "Adrenergic Agonists", "relevance": "LOW"}, {"id": "M20504", "name": "Neurotransmitter Agents", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Resp", "name": "Respiratory System Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": true}